Real-world comparative effectiveness of tofacitinib, tumour necrosis factor inhibitors, and interleukin 17 inhibitors among patients with axial spondylarthritis and psoriatic arthritis

First published 15/11/2024

Last updated 18/02/2025

EU PAS number:

EUPAS1000000226

Study

Ongoing

Documents

Study protocol

Initial protocol

A3921446_Protocol_V1_23AUG2024_ REDACTED.pdf

English (1.1 MB - PDF)View document

Updated protocol

A3921446 Protocol V 2.0 dated 03 JAN 2025_FINAL_Redacted.pdf

First published: 03/02/2025

English (886.66 KB - PDF)View document

Study results

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs